Lv11
46 积分 2024-06-26 加入
EZH2-mediated development of therapeutic resistance in cancer
7天前
已完结
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
13天前
已完结
PDX models for functional precision oncology and discovery science
14天前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
26天前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
1个月前
已完结
The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally
1个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
1个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
1个月前
已完结
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
1个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
1个月前
已完结
皖公网安备34019202002308
